Prof. Dr. Rainer Riedl

Arbeit an der ZHAW

Tätigkeit

• Leiter Kompetenzzentrum für Wirkstoffforschung
• Leiter Fachgruppe Organische Chemie und Medizinalchemie

Netzwerk

Mitglied in Netzwerken

• Schweizerische Akademie der Technischen Wissenschaften
• Biotechnet Switzerland
• Studienstiftung des Deutschen Volkes
• Swiss Chemical Society
• Alexander von Humboldt Foundation

ORCID digital identifier

ORCID ID: 0000-0003-2534-1963

Social Media

linkedin

Projekte

• NEXTPro / Projektleiter:in / laufend
• Targeting the innate immune system for Multiple Sclerosis / Projektleiter:in / laufend
• Small molecules targeting CD93-signaling for the treatment of acute myeloid leukemia / Projektleiter:in / laufend
• Peptidic active ingredients III / Projektleiter:in / abgeschlossen
• Alzheimer's dementia / Projektleiter:in / abgeschlossen
• Evaluation of the potential of PROTACs / Projektleiter:in / abgeschlossen
• Peptidic active ingredients II / Projektleiter:in / abgeschlossen
• Antibiotika gegen hochresistente Gram-negative Bakterien / Projektleiter:in / abgeschlossen
• Innovative Immunotherapy Approach / Projektleiter:in / abgeschlossen
• Therapie für den NRAS-Melanom-Subtyp / Projektleiter:in / abgeschlossen
• Synthesis of peptidic active ingredients / Projektleiter:in / abgeschlossen
• Plattform zur Identifizierung von Wirkstofftargets / Projektleiter:in / abgeschlossen
• Protease-Inhibitoren gegen SARS-CoV-2 / Projektleiter:in / abgeschlossen
• Extrazelluläre Vesikel für den Transport von antimikrobiellen Proteinen zum Zielgewebe / Stellv. Projektleiter:in / abgeschlossen
• Developing novel and effective therapies for treatment of childhood brain cancers / Projektleiter:in / abgeschlossen
• Entwicklung neuer Therapieansätze zur Behandlung von Krebs / Projektleiter:in / abgeschlossen
• Entwicklung einer neuartigen Behandlung gegen pathologische Haut- und Sehnenkalzifizierung auf Basis eines Gasotransmitters / Projektleiter:in / abgeschlossen
• Plants and Minerals in Byzantine Popular Pharmacy. A New Multidisciplinary Approach / Stellv. Projektleiter:in / abgeschlossen
• Entwicklung von niedermolekularen Verbindungen zur Blockierung des CD93 Signalwegs bei Leukämiepatienten / Projektleiter:in / abgeschlossen
• Inflammasominhibitoren - Entwicklung neuer Hemmstoffe / Projektleiter:in / abgeschlossen
• Modulatoren der MMP-Hemopexin-Domäne / Projektleiter:in / abgeschlossen
• Neue Antibiotika: RNA-Polymerase-Inhibitoren / Projektleiter:in / abgeschlossen
• Behandlung von Brandwunden / Projektleiter:in / abgeschlossen
• Antivirale Wirkstoffe / Projektleiter:in / abgeschlossen
• MMP-Inhibitor-Hydrogel zur Wundheilung / Projektleiter:in / abgeschlossen
• Induktion der Wirkstoffbildung bei Actinomyceten / Stellv. Projektleiter:in / abgeschlossen
• Ein topisches Antiinfektiva / Projektleiter:in / abgeschlossen
• Morbillivirus cell entry machinery: mechanisms, structures and antiviral drug discovery / Co-Projektleiter:in / abgeschlossen
• Identifizierung und Charakterisierung von Wirkstoffen aus Actinomyceten aus der Schweiz gegen pathogene Bakterien / Projektleiter:in / abgeschlossen
• Virus cell entry machinery: antiviral drug discovery / Projektleiter:in / abgeschlossen
• Novel Antimicrobials for Life-Threatening Infections / Projektleiter:in / abgeschlossen
• Dynamic combinatorial chemistry in drug discovery / Projektleiter:in / abgeschlossen
• New antileishmanial and antitrypanosomal drugs / Projektleiter:in / abgeschlossen
• New drugs for the treatment of protozoal infections derived from natural products / Projektleiter:in / abgeschlossen
• Kinetische Struktur-Aktivitäts-Beziehungen und röntgenkristallographische Bestimmung des Bindungsmodus von niedermolekularen Wirkstoffmolekülen / Projektleiter:in / abgeschlossen
• Development of high temperature resistant, synergistic biocidal products for protection of PVC against microbial infestation for commercial product applications / Projektleiter:in / abgeschlossen
• HIT to LEAD to Preclinical Candidate development of a Transcription Repressor Inhibitory Compound (TRIC) that increases antibiotic susceptibility of multidrug resistant staphylococci / Projektleiter:in / abgeschlossen
• Forschungs- und Entwicklungsarbeiten auf dem Gebiet von potentiellen Wirkstoffen gegen Diabetes / Projektleiter:in / abgeschlossen
• Prevention of undesired interactions between biocides and additives in synthetic materials to improve efficacy and to reduce the necessary amount of biocides / Projektleiter:in / abgeschlossen
• Development of a software to analyse chemical and biological data: CyBy2 / Projektleiter:in / abgeschlossen
• HIT to LEAD to Candidate development of a Transcription Repressor Inhibitory Compound (TRIC), which switches off bacterial resistance to a broad band antibiotic / Projektleiter:in / abgeschlossen
• Isolation, Identifikation und medizinalchemische Optimierung von biogenen Wirkstoffen / Projektleiter:in / abgeschlossen
• Identification of novel targets and drug candidates against multi-drug resistant bacteria / Projektleiter:in / abgeschlossen

Publikationen

Beiträge in wissenschaftlicher Zeitschrift, peer-reviewed

• Scherer, M. et al. (2026) 'Protection against lethal canine distemper virus infection by a dual epitope-targeting synthetic antibody', Nature Communications, 17(1), p. 103. doi: 10.1038/s41467-025-67600-z.
• Nasi, S. et al. (2025) 'Allosteric activators of cystathionine γ lyase to augment endogenous hydrogen sulfide and inhibit pathologic calcification', Pharmacological Research, 219(107869). doi: 10.1016/j.phrs.2025.107869.
• Rimle, L. et al. (2025) 'Dissecting structural requirements of leucinostatin A derivatives for antiprotozoal activity and mammalian toxicity', Journal of Medicinal Chemistry, 68(4), pp. 4237–4258. doi: 10.1021/acs.jmedchem.4c01989.
• Fischer, T. et al. (2024) 'Phthalimide derivatives as a new class of papain‐like protease inhibitors in SARS‐CoV‐2', Archiv der Pharmazie, 358(1), p. e2400714. doi: 10.1002/ardp.202400714.
• Fischer, T. et al. (2024) 'Phthalimide derivatives as a new class of papain-like protease inhibitors in SARS-CoV-2', Archiv der Pharmazie, 358(1), p. e2400714. doi: 10.1002/ardp.202400714.
• Pliatsika, D., Blatter, C. and Riedl, R. (2024) 'Targeted protein degradation : current molecular targets, localization, and strategies', Drug Discovery Today, 29(11), p. 104178. doi: 10.1016/j.drudis.2024.104178.
• Kalbermatter, D. et al. (2023) 'Structure and supramolecular organization of the canine distemper virus attachment glycoprotein', Proceedings of the National Academy of Sciences of the United States of America, 120(6), p. e2208866120. doi: 10.1073/pnas.2208866120.
• Sabani, B. et al. (2023) 'A novel surface functionalization platform to prime extracellular vesicles for targeted therapy and diagnostic imaging', Nanomedicine: Nanotechnology, Biology and Medicine, 47(102607). doi: 10.1016/j.nano.2022.102607.
• Bagatella, S. et al. (2022) 'Bovine neutrophil chemotaxis to Listeria monocytogenes in neurolisteriosis depends on microglia-released rather than bacterial factors', Journal of Neuroinflammation, 19(304). doi: 10.1186/s12974-022-02653-1.
• Kiss, C. et al. (2022) 'Structure of a hydrophobic leucinostatin derivative determined by host lattice display', Acta Crystallographica. Section D: Structural Biology, 78(12), pp. 1439–1450. doi: 10.1107/S2059798322010762.
• Brand, M. et al. (2022) 'Discovery of a dual SENP1 and SENP2 inhibitor', International Journal of Molecular Sciences, 23(20), p. 12085. doi: 10.3390/ijms232012085.
• Fischer, T. and Riedl, R. (2022) 'Paracelsus" legacy in the faunal realm : drugs deriving from animal toxins', Drug Discovery Today, 27(2), pp. 567–575. doi: 10.1016/j.drudis.2021.10.003.
• Shrestha, N. et al. (2021) 'Highly potent host-specific small-molecule inhibitor of paramyxovirus and pneumovirus replication with high resistance barrier', mBio, 12(6), p. e0262121. doi: 10.1128/mBio.02621-21.
• Brand, M. et al. (2021) 'Antiprotozoische Struktur‐Aktivitäts‐Beziehungen von synthetischen Leucinostatin‐Derivaten und Aufklärung ihres Wirkprinzips', Angewandte Chemie, 133(28), pp. 15741–15749. doi: 10.1002/ange.202102153.
• Neidhart, B. et al. (2021) 'Tissue inhibitor of metalloproteinase (TIMP) peptidomimetic as an adjunctive therapy for infectious keratitis', Biomacromolecules, 22(2), pp. 629–639. doi: 10.1021/acs.biomac.0c01473.
• Brand, M. et al. (2021) 'Antiprotozoal structure–activity relationships of synthetic leucinostatin derivatives and elucidation of their mode of action', Angewandte Chemie: International Edition, 60(28), pp. 15613–15621. doi: 10.1002/anie.202102153.
• Zizzari, A. T. et al. (2021) 'New perspectives in oral peptide delivery', Drug Discovery Today, 26(4), pp. 1097–1105. doi: 10.1016/j.drudis.2021.01.020.
• Shrestha, N. et al. (2021) 'Antiviral screen against canine distemper virus-induced membrane fusion activity', Viruses, 13(1), p. 128. doi: 10.3390/v13010128.
• Arn, F. et al. (2020) 'Isolation and identification of actinomycetes strains from Switzerland and their biotechnological potential', Chimia, 74(5), pp. 382–390. doi: 10.2533/chimia.2020.382.
• Fischer, T. and Riedl, R. (2020) 'Challenges with matrix metalloproteinase inhibition and future drug discovery avenues', Expert Opinion on Drug Discovery, 16(1), pp. 75–88. doi: 10.1080/17460441.2020.1819235.
• Kalbermatter, D. et al. (2020) 'Cryo-EM structure of the prefusion state of canine distemper virus fusion protein ectodomain', Journal of Structural Biology: X, 4, p. 100021. doi: 10.1016/j.yjsbx.2020.100021.
• Lindenmann, U. et al. (2020) 'Discovery of a class of potent and selective non‐competitive sentrin‐specific protease 1 inhibitors', ChemMedChem, 15(8), pp. 675–679. doi: 10.1002/cmdc.202000067.
• Fischer, T. et al. (2019) 'High consistency of structure-based design and x-ray crystallography : design, synthesis, kinetic evaluation and crystallographic binding mode determination of biphenyl-N-acyl-β-D-glucopyranosylamines as glycogen phosphorylase inhibitors', Molecules, 24(7), p. 1322. doi: 10.3390/molecules24071322.
• Fischer, T. and Riedl, R. (2019) 'Inhibitory antibodies designed for matrix metalloproteinase modulation', Molecules, 24(12), p. 2265. doi: 10.3390/molecules24122265.
• Höck, S. and Riedl, R. (2019) 'CyBy2 : a strongly typed, purely functional framework for chemical data management', Journal of Cheminformatics, 11(80). doi: 10.1186/s13321-019-0403-2.
• Fischer, T., Gazzola, S. and Riedl, R. (2019) 'Approaching target selectivity by de novo drug design', Expert Opinion on Drug Discovery, 14(8), pp. 791–803. doi: 10.1080/17460441.2019.1615435.
• Fischer, T., Senn, N. and Riedl, R. (2019) 'Design and structural evolution of matrix metalloproteinase inhibitors', Chemistry – A European Journal, 25(34), pp. 7960–7980. doi: 10.1002/chem.201805361.
• Gall, F. et al. (2019) 'Von der Natur inspiriertes Wirkstoffdesign : kristallographische Detektion eines selbstgenerierten Inhibitor‐Grundgerüsts', Angewandte Chemie, 131(12), pp. 4091–4096. doi: 10.1002/ange.201812348.
• Gall, F. et al. (2019) 'Drug design inspired by nature : crystallographic detection of an auto‐tailored protease inhibitor template', Angewandte Chemie: International Edition, 58(12), pp. 4051–4055. doi: 10.1002/anie.201812348.
• Kalbermatter, D. et al. (2018) 'Primary resistance mechanism of the canine distemper virus fusion protein against a small-molecule membrane fusion inhibitor', Virus Research, 259, pp. 28–37. doi: 10.1016/j.virusres.2018.10.003.
• Agnello, S. et al. (2018) 'Eine strukturelle Evaluierung medizinalchemischer Strategien gegen Wirkstoffresistenzen', Angewandte Chemie, 131(11), pp. 3336–3383. doi: 10.1002/ange.201802416.
• Agnello, S. et al. (2018) 'A Structural view on medicinal chemistry strategies against drug resistance', Angewandte Chemie, 58(11), pp. 3300–3345. doi: 10.1002/anie.201802416.
• Chellat, M. F. and Riedl, R. (2017) 'Pseudouridimycin : das erste Nukleosid-Analogon, das bakterielle RNA-Polymerase selektiv inhibiert', Angewandte Chemie, 129(43), pp. 13364–13366. doi: 10.1002/ange.201708133.
• Chellat, M. F. and Riedl, R. (2017) 'Pseudouridimycin : the first nucleoside analogue that selectively inhibits bacterial RNA polymerase', Angewandte Chemie: International Edition, 56(43), pp. 13184–13186. doi: 10.1002/anie.201708133.
• Fischer, T. and Riedl, R. (2017) 'Cover profile : targeted fluoro positioning for the discovery of a potent and highly selective matrix metalloproteinase inhibitor', ChemistryOpen, 6(2), p. 167. doi: 10.1002/open.201700042.
• Fischer, T. and Riedl, R. (2017) 'Cover picture : targeted fluoro positioning for the discovery of a potent and highly selective matrix metalloproteinase inhibitor (ChemistryOpen 2/2017)', ChemistryOpen, 6(2), p. 165. doi: 10.1002/open.201700043.
• Fischer, T. and Riedl, R. (2017) 'Targeted fluoro positioning for the discovery of a potent and highly selective matrix metalloproteinase inhibitor', ChemistryOpen, 6(2), pp. 192–195. doi: 10.1002/open.201600158.
• Fischer, T. and Riedl, R. (2017) 'Development of a non-hydroxamate dual matrix metalloproteinase (MMP)-7/-13 inhibitor', Molecules, 22(9). doi: 10.3390/molecules22091548.
• Senn, N. et al. (2017) 'Targeted polypharmacology : discovery of a highly potent non-hydroxamate dual matrix metalloproteinase (MMP)-10/-13 inhibitor', Journal of Medicinal Chemistry, 60(23), pp. 9585–9598. doi: 10.1021/acs.jmedchem.7b01001.
• Abu Eid, S. et al. (2017) 'Emodin : a compound with putative antidiabetic potential, deteriorates glucose tolerance in rodents', European Journal of Pharmacology, 798, pp. 77–84. doi: 10.1016/j.ejphar.2017.01.022.
• Chellat, M. F., Raguž, L. and Riedl, R. (2016) 'Antibiotikaresistenzen gezielt überwinden', Angewandte Chemie, 128(23), pp. 6710–6738. doi: 10.1002/ange.201506818.
• Fischer, T. and Riedl, R. (2016) 'Molecular recognition of the catalytic zinc(II) ion in MMP-13 : structure-based evolution of an allosteric inhibitor to dual binding mode inhibitors with improved lipophilic ligand efficiencies', International Journal of Molecular Sciences, 17(3/314). doi: 10.3390/ijms17030314.
• Chellat, M. F., Raguž, L. and Riedl, R. (2016) 'Targeting antibiotic resistance', Angewandte Chemie: International Edition, 55(23), pp. 6600–6626. doi: 10.1002/anie.201506818.
• Lanz, J. and Riedl, R. (2015) 'Merging allosteric and active site binding motifs : de novo generation of target selectivity and potency via natural-product-derived fragments', ChemMedChem, 10(3), pp. 451–454. doi: 10.1002/cmdc.201402478.
• Todorova, M. et al. (2015) 'Highly oxygenated sesquiterpenes in Artemisia alba Turra', Phytochemistry, 110, pp. 140–149. doi: 10.1016/j.phytochem.2014.12.008.
• Fischer, T. and Riedl, R. (2013) 'Strategic targeting of multiple water-mediated interactions : a concise and rational structure-based design approach to potent and selective MMP-13 inhibitors', ChemMedChem, 8(9), pp. 1457–1461. doi: 10.1002/cmdc.201300278.
• Höck, S. and Riedl, R. (2012) 'chemf : a purely functional chemistry toolkit', Journal of Cheminformatics, 4(38). doi: 10.1186/1758-2946-4-38.
• Höck, S. and Riedl, R. (2012) 'CyBy2 : a structure-based data management tool for chemical and biological data', Chimia, 66(3), pp. 132–134. doi: 10.2533/chimia.2012.132a.
• Höck, S. et al. (2010) 'Thermal cleavage of the Fmoc protection group', Chimia, 64(3), pp. 200–202. doi: 10.2533/chimia.2010.200.
• Heuser, S. et al. (2006) 'Synthesis of novel cyclopropylic sulfones and sulfonamides acting as glucokinase activators', Tetrahedron Letters, 47(16), pp. 2675–2678. doi: 10.1016/j.tetlet.2006.02.110.
• Supekova, L. et al. (2002) 'Genomic effects of polyamide/DNA interactions on mRNA expression', Chemistry & Biology, 9(7), pp. 821–827. doi: 10.1016/S1074-5521(02)00174-6.
• Berkessel, A. and Riedl, R. (2000) 'Combinatorial de novo synthesis of catalysts : how much of a hit-structure is needed for activity?', Journal of Combinatorial Chemistry, 2(3), pp. 215–219. doi: 10.1021/cc990073i.
• Riedl, R., Tappe, R. and Berkessel, A. (1998) 'Probing the scope of the asymmetric dihydroxylation of polymer-bound olefins : monitoring by HRMAS NMR allows for reaction control and on-bead measurement of enantiomeric excess', Journal of the American Chemical Society, 120(35), pp. 8994–9000. doi: 10.1021/ja980183d.
• Berkessel, A. and Riedl, R. (1997) 'Fluoreszenz-Reporter für Phosphodiesterase-Aktivität', Angewandte Chemie, 109(13-14), pp. 1518–1520. doi: 10.1002/ange.19971091313.
• Berkessel, A. and Riedl, R. (1997) 'Fluorescence reporters for phosphodiesterase activity', Angewandte Chemie: International Edition, 36(13-14), pp. 1481–1483. doi: 10.1002/anie.199714811.

Bücher, peer-reviewed

Riedl, R. (1998) Kombinatorische de novo Synthese von künstlichen Phosphorsäurediesterasen : Inaugural-Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Universität zu Köln. Doctoral dissertation. Universität zu Köln. Available at: http://kups.ub.uni-koeln.de/573/.

Weitere Publikationen

• Hess, S. et al. (2025) A NanoBRET-based assay monitoring interactions in the USP18 signaling hub identifies the first cell-penetrant small molecule compromising USP18/ISG15 binding. bioRxiv. doi: 10.1101/2025.03.30.646166.
• Riedl, R. (2023) 'Development of small-molecule drugs for the treatment of leukemia', Transfer, 2023(1), p. 7. doi: 10.21256/zhaw-30047.
• Brand, M. et al. (2021) Rücktitelbild: Antiprotozoische Struktur-Aktivitäts-Beziehungen von synthetischen Leucinostatin-Derivaten und Aufklärung ihres Wirkprinzips (Angew. Chem. 28/2021). Wiley. doi: 10.1002/ange.202104896.
• Brand, M. et al. (2021) Back Cover: Antiprotozoal structure–activity relationships of synthetic leucinostatin derivatives and elucidation of their mode of action (Angew. Chem. Int. Ed. 28/2021). Wiley. doi: 10.1002/anie.202104896.
• Gall, F. et al. (2019) 'Durch die Natur inspiriertes Wirkstoffdesign', Transfer, 2019(1), p. 6. doi: 10.21256/zhaw-30046.
• Gall, F. M. et al. (2019) Titelbild: Von der Natur inspiriertes Wirkstoffdesign : kristallographische Detektion eines selbstgenerierten Inhibitor‐Grundgerüsts (Angew. Chem. 12/2019). Wiley. doi: 10.1002/ange.201901671.
• Gall, F. et al. (2019) 'Cover picture : drug design inspired by nature : crystallographic detection of an auto‐tailored protease inhibitor template (Angew. Chem. Int. Ed. 12/2019)', Angewandte Chemie: International Edition, 58(12), p. 3653. doi: 10.1002/anie.201901671.
• Lanz, J. and Riedl, R. (2015) 'Cover picture: Merging allosteric and active site binding motifs : de novo generation of target selectivity and potency via natural‐product‐derived fragments (ChemMedChem 3/2015)'. doi: 10.1002/cmdc.201590003.
• Riedl, R. (2014) 'Nicht nur Metalloproteasen im Visier', Chemie Plus, 2014(4), pp. 30–31.
• Riedl, R. (2014) 'Fighting the resistance', Horizon 2020 Projects, 2014(4), p. 130.
• Riedl, R. (2013) 'Bridging the disciplines : cancer diagnostics & treatment', Pan European Networks: Science & Technology, 7, pp. 240–241.
• Riedl, R. and Höck, S. (2013) 'CyBy² : clevere Handhabung strukturbasierter Datensätze', Transfer, 2013(1), p. 3. doi: 10.21256/zhaw-2864.
• Fischer, T. and Riedl, R. (2013) Back Cover: Strategic targeting of multiple water‐mediated interactions : a concise and rational structure‐based design approach to potent and selective MMP‐13 inhibitors (ChemMedChem 9/2013). Wiley. doi: 10.1002/cmdc.201390039.
• Riedl, R. (2013) 'Drug discovery through a chemist's eyes', International Innovation - EuroFocus, 18, p. 103.
• Riedl, R. (2013) 'Organic chemistry : the heart and soul of drug discovery', International Innovation - EuroFocus, 18, pp. 104–105.
• Fischer, T. and Riedl, R. (2012) 'Design, synthesis and biological testing of novel MMP-inhibitors', in Fall Meeting 2012 of the Swiss Chemical Society, Zurich, 13 September 2012.
• Riedl, R. and Fischer, T. (2012) 'Structure based design and synthesis of novel MMP inhibitors', in 19th EuroQSAR: «Knowledge Enabled Ligand Design», Vienna, Austria, 26-30 August 2012.
• Riedl, R. and Brand, M. (2012) 'Synthese und medizinalchemische Optimierung von Tetrazyklinanaloga', À Jour: SVC - Chemie, Life Sciences & Biotechnologie, 2012(1), pp. 10–11.
• Riedl, R. and Höck, S. (2012) 'Enhancing CyBy2 : visualization of structure activity relationships of large datasets', in Fall Meeting 2012 of the Swiss Chemical Society, Zurich, 13 September 2012.
• Riedl, R. and Höck, S. (2011) 'CyBy2 : a modular rich client for the chemical and biological information management', in Fall Meeting 2011 of the Swiss Chemical Society, Lausanne, 9 September 2011.
• Riedl, R., Brand, M. and Sephton, M. (2011) 'Synthesis of tetracycline analogues', in Fall Meeting 2011 of the Swiss Chemical Society, Lausanne, 9 September 2011.
• Riedl, R. et al. (2011) 'Structure based design and synthesis of novel MMP inhibitors', in Fall Meeting 2011 of the Swiss Chemical Society, Lausanne, 9 September 2011.
• Riedl, R., Höck, S. and Kunz, L. (2010) 'Profiling H-bond properties of fragments', in Fall Meeting 2012 of the Swiss Chemical Society, Zurich, 16 September 2010.
• Riedl, R. and Fischer, T. (2010) 'Fragment based scaffold hopping in drug discovery', in Fall Meeting 2012 of the Swiss Chemical Society, Zurich, 16 September 2010.

Mündliche Konferenzbeiträge und Abstracts

• Ehirchiou, D. et al. (2025) 'Positive allosteric modulators (PAMS) of cystathionine gamma lyase (CSE) increase hydrogen sulfide (H2S) and inhibit NLRP3 activation', in Annals of the Rheumatic Diseases. Elsevier, pp. 116–117. doi: 10.1016/j.ard.2025.05.154.
• Ehirchiou, D. et al. (2025) 'Development of allosteric activators of cystathionine γ lyase (CSE) to augment hydrogen sulfide (H2S) and inhibit pathologic cartilage calcification', in Annals of the Rheumatic Diseases. Elsevier, pp. 112–113. doi: 10.1016/j.ard.2025.05.149.
• Ehirchiou, D. et al. (2025) 'Development of allosteric activators of cystathionine γ lyase (CSE) to augment hydrogen sulfide (H2S) and inhibit pathologic cartilage calcification', in Osteoarthritis and Cartilage. Elsevier, p. S452. doi: 10.1016/j.joca.2025.02.660.
• Riedl, R. (2024) 'Competencies in drug discovery', in tfz Innovation Inside Pharma, Rotkreuz, Switzerland, 23 October 2024.
• Rimle, L. et al. (2024) 'Molecular basis for leucinostatin A toxicity in mammals', in Biochimica et Biophysica Acta (BBA) - Bioenergetics. Elsevier. doi: 10.1016/j.bbabio.2024.149316.
• Riedl, R. (2024) 'Center of excellence for drug discovery', in Competencies in Drug Discovery, Wädenswil, Switzerland, 6 June 2024.
• Bagatella, S. et al. (2022) 'Microglia, rather than bacterial factors, mediate bovine neutrophil chemotaxis in neurolisteriosis', in Journal of Comparative Pathology. Elsevier, p. 61. doi: 10.1016/j.jcpa.2023.03.073.
• Abu Eid, S. et al. (2016) 'Emodin, a compound with acclaimed antidiabetic potential, deteriorates glucose tolerance in obese mice', in Diabetologia. Springer, p. S343. doi: 10.1007/s00125-016-4046-9.
• Abu Eud, S. et al. (2015) 'Emodin, eine mutmaßlich anti-diabetisch wirksame Verbindung, beeinträchtigt die Glukosetoleranz adipöser Mäuse', in Wiener Klinische Wochenschrift. Springer, p. 735. doi: 10.1007/s00508-015-0838-z.
• Riedl, R. (2013) 'Tackling antibiotic resistance', in ILMAC 2013, 19. Internationale Fachmesse für Laboratoriums- und Verfahrenstechnik, Messtechnik und Automatik in der Chemie (ILMAC), Basel, 24.-27. September 2013.
• Riedl, R. (2011) 'Drug discovery in the academic setting', in 3. Wädenswiler Chemietag «Medizinalchemie - Fokus Wirkstoffentwicklung», Wädenswil, 16. Juni 2011.
• Riedl, R. (2010) 'Structure based drug design', in Biotech in Medicine - Olten Meeting, Olten, 24. November 2010.
• Riedl, R. (2010) 'Structure activity relationship within a gene switching system', in Symposium - Synthetic Biotechnology, Basel, 18.-19. November 2010.

Patente und Patentanmeldungen

• Adams, Michael; Kemmler, Michael; Tobler, Andreas; Pliatsika, Dimanthi; Riedl, Rainer,

  2025.

  Compounds for treatment of cancer.

  Patentnummer WO2025172389 A1

  (2025-08-21)

  .

• Riedl, Rainer; Brand, Michael; Bommeli, Elias; Ochsenbein, Adrian; Riether, Carsten,

  2024.

  CD93 inhibitors.

  Patentnummer WO2024115637 A1

  (2024-06-06)

  .

• Adams, Michael; Kemmler, Michael; Pliatsika, Dimanthi; Riedl, Rainer,

  2024.

  Topical treatment of skin cancer using oligopeptides.

  Patentnummer WO2024033418 A1

  (2024-02-15)

  .

• Knechtle, Philipp; Gombert, Frank Otto; Riedl, Rainer; Lindenmann, Urs; Krebs, Walter; Wipfli, Dennis; Albert, Ina; Wegmann, Sandro; Schmid, Andrina,

  2023.

  Novel antifungal compounds.

  Patentnummer WO2023001905 A1

  (2023-01-26)

  .

• So, Alexander; Busso, Natalie; Nasi, Sonia; Brand, Michael; Gall, Flavio Max; Riedl, Rainer; Germann, Stefan,

  2022.

  Methods and compositions for treating conditions associated with hypermineralization.

  Patentnummer WO2022194953 A1

  (2022-09-22)

  .

• So, Alexander; Busso, Natalie; Nasi, Sonia; Brand, Michael; Gall, Flavio; Riedl, Rainer,

  2022.

  Methods and compositions for treating conditions associated with hypermineralization.

  Patentnummer EP4059498 A1

  (2022-09-21)

  .

• Adams, Michael; Kemmler, Michael; Riedl, Rainer; Pliatsika, Dimanthi; Imanidis, Georgios; Herzig, Susanne; Kaiser, Marcel; Mäser, Pascal,

  2022.

  Treatment of skin disorders.

  Patentnummer WO2022167656 A1

  (2022-08-11)

  .

• Agnello, Stefano; Adams, Michael; Kaiser, Marcel; Mäser, Pascal; Urban, Alexander; Raguz, Luka; Riedl, Rainer,

  2018.

  Antiprotozoal compounds.

  Patentnummer EP3345917 A1

  (2018-07-11)

  .

• Schneider, Peter; Riedl, Rainer; Tigges, Marcel; Gitzinger, Marc; Pieren, Michel; Levi, Assaf; Sephton, Mark; Schellhorn, Birgit; Züger, Patrik; Brand, Michael; Gygax, Daniel; Spies, Peter,

  2015.

  Composition for treatment of pathogens that are resistant to tetracyclines.

  Patentnummer EP2950793 A1

  (2015-12-09)

  .

• Weichert, Andreas Gerhard; Barrett, David Gene; Heuser, Stefan; Riedl, Rainer; Tebbe, Mark Joseph; Zaliani, Andrea,

  2011.

  Substituted arylcyclopropylacetamides as glucokinase activators.

  Patentnummer EP1585739 B1

  (2011-04-20)

  .

• Weichert, Andreas; Barrett, David; Heuser, Stefan; Riedl, Rainer; Tebbe, Mark; Zaliani, Andrea,

  2004.

  Heteroaryl compounds.

  Patentnummer WO2004063194 A1

  (2004-07-29)

  .

Interessenbindungen

Aktuelle Interessenbindungen

• ULTIMATE MEDICINE AG: Beratung
  Beratungstätigkeit im Bereich der pharmazeutischen Wirkstoffforschung und Wirkstoffentwicklung für die Firma Ultimate Medicine AG, gegründet und registriert in der Schweiz unter der Firmennummer CHE-438.939.011., Zürich
  08 / 2024 - heute
• Cure-GMPPB Association: Mitglied des wissenschftlichen Beirats
  Beratungstätigkeit im Bereich der pharmazeutischen Wirkstoffforschung und Wirkstoffentwicklung. Als Mitglied des wissenschaftlichen Beirats berate ich bei der Festlegung von Forschungsschwerpunkten, bei Förderentscheidungen und bei der Überwachung des Projektfortschritts, um wissenschaftliche Stringenz und langfristige Wirkung sicherzustellen., Männedorf
  07 / 2026 - 07 / 2027

Vergangene Interessenbindungen

Czech Academy of Sciences: Beratung
Mitglied der Evaluierungskommission der Tschechischen Akademie der Wissenschaften für die Evaluierung des Instituts für Organische Chemie und Biochemie, Prag, Prag
04 / 2025 - 12 / 2025

Zurück